Data: Coronavac Produces Antibodies Against Covid in 97 Percent of Subjects

Last week, Pfizer and Moderna released more advanced preliminary and encouraging phase 3 results based on interim data analysis. Both showed efficacy over 90 percent, but the details have not yet been published in a scientific journal.

RIO DE JANEIRO, BRAZIL - The vaccine against Covid-19 from the Chinese manufacturer Sinovac is safe and is able to produce an immune response in the body 28 days after its administration in 97 percent of cases, according to a peer-reviewed article published on Tuesday, November 17th in the Lancet Infectious Diseases scientific journal.

The results are the based on the analysis of phase 1 and 2 clinical trials conducted in China in April and May with 744 healthy volunteers aged 18 to 59 and with no history of Sars-CoV-2 coronavirus infection.

Although the Coronavac vaccine is . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?